The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Prof Kamm is a gastroenterologist interested in developing improved treatments for gastrointestinal and pelvic floor disorders, such as inflammatory bowel disease and functional disorders. He runs basic science, translational and clinical strands of research in parallel across the same areas of interest, developing new treatments that encompass physiological, pharmacological, surgical and psychological therapies.
I am a molecular biologist interested in understanding how cells are able to actively kill themselves, and how cells make the decision to live or die. Understanding how cells kill themselves will ultimately lead to better therapies designed to kill cancer
I am an infectious diseases physician and basic scientist interested in the immunopathogenesis of HIV and hepatitis B virus. My work focuses on HIV viral reservoirs and immune reconstitution and the adaptive immune response to hepatitis B virus.
I am a pharmacologist-cell biologist-molecular biologist and chemist examining the metabolism of iron in normal and neoplastic cells and the development of iron chelators for the treatment of a variety of diseases e.g., ?-thalassaemia and cancer.
I am a cancer biologist determining the mechanisms of anti-cancer drug action and drug resistance and performing preclinical studies to identify novel chemotherapeutic drug combinations for the treatment of cancer.
I am a cellular immunologist with expertise in antigen processing-presentation, CTL determinant selection and immunodominance, T cell differentiation and, cancer immunotherapeutic trials and cancer vaccine development.
I am a cancer cell biologist investigating molecular mechanisms of leukaemia cell resistance to chemotherapeutic drugs, and novel strategies for the management of high risk or relapsed disease. For these purposes I have developed orthotopic xenograft mode
I am a molecular geneticist investigating the development of cancer, the mechanisms controlling apoptosis, and how impaired apoptosis contributes to tumorigenesis and the resistance of cancer cells to therapy.